2015 Subscriptions availableOrder the next volume of Antiviral Therapy today.
ARV access in resource-poor countriesHighly anticipated special issue with UNAIDS now available
Follow us on TwitterInternational Medical Press is now on Twitter. Join our conversation today.
International Medical Press publishes two peer-reviewed journals:
Antiviral Therapy is one of the leading journals in virology (2013 ISI impact factor: 3.14). The journal is devoted to publishing high quality articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases.
Antiviral Chemistry & Chemotherapy is an online peer-reviewed journal publishing the results of original research concerned with the biochemistry, mode of action, chemistry, pharmacology and virology of antiviral compounds.
♦ Online submission and manuscript tracking via ScholarOne Manuscripts™
♦ Leading Editorial Boards ensuring high-quality standards
♦ Immediate online publication of all non-commissioned articles
♦ Inclusion in major indexing and abstracting services
♦ Worldwide readership
Recently published in Antiviral Therapy
Rimsky et al. report long-term resistance to rilpivirine in the ECHO/THRIVE Phase III trials. At 96 weeks, resistance patterns were consistent with 48-week data, and suggest most virological failures and resistance-associated mutations occur during the first year of treatment. Overall, the evidence demonstrates rilpivirine is non-inferior to existing therapies for HIV-infected, treatment-naive patients. Read more here.
The Editorial Office welcomes queries about publishing supplements within the journal. Please visit the Supplements page for more information.